Intensity Therapeutics Inc banner
Financial profile · Q3 FY2026

A pre-revenue clinical developer funded by equity amid recurring research and trial costs

Intensity’s financial model remains pre-commercial: research and development and public-company costs consume cash, with no product revenue to fund them. It has relied on equity financing rather than internally generated cash, linking clinical activity, liquidity, and dilution.

What is developing

The latest quarter shows higher development spending as limited INVINCIBLE-3 enrollment resumed and a new manufacturing batch began. This changes the pace of spending, but not the underlying pre-revenue, externally funded model.

What matters next

Whether additional financing supports broader trial enrollment while covering continued operating cash use.

USD
Metric FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
0 0 0 0 0 0
(6.2m) (8m) (7.6m) (8.3m) (16.6m) (12m)
(1.2m) (2.2m) (2.4m) (3.5m) (6.1m) (5.2m)
R&D
(5.1m) (5.9m) (5.1m) (4.8m) (10.5m) (6.8m)
(6.2m) (8m) (7.6m) (8.3m) (16.6m) (12m)
74k 2.6k (80k) 19k 314k 180k
— — 82k 305k — —
— — 0 (2.3m) 0 —
118.8k 115.5k 48k 24k 3k 186k
(6m) (7.9m) (7.6m) (10.5m) (16.3m) (11.6m)
— — — — 0 —
(6m) (7.9m) (7.6m) (10.5m) (16.3m) (11.6m)
(6m) (7.9m) (7.6m) (11.9m) (16.3m) (11.6m)
(11.50) (15.06) (14.47) (21.63) (29.24) (8.56)